ID   RREB1_HUMAN             Reviewed;        1687 AA.
AC   Q92766; A2RRF5; E2GM80; E2GM81; O75567; O75568; Q5VYB2; Q6BEP5; Q6BEP6;
AC   Q6BEP8; Q86SU2; Q9Y474;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   10-JUL-2007, sequence version 3.
DT   28-JUN-2023, entry version 196.
DE   RecName: Full=Ras-responsive element-binding protein 1;
DE            Short=RREB-1;
DE   AltName: Full=Finger protein in nuclear bodies;
DE   AltName: Full=Raf-responsive zinc finger protein LZ321;
DE   AltName: Full=Zinc finger motif enhancer-binding protein 1;
DE            Short=Zep-1;
GN   Name=RREB1; Synonyms=FINB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9305772; DOI=10.1016/s0378-1119(97)00172-8;
RA   Fujimoto-Nishiyama A., Ishii S., Matsuda S., Inoue J., Yamamoto T.;
RT   "A novel zinc finger protein, Finb, is a transcriptional activator and
RT   localized in nuclear bodies.";
RL   Gene 195:267-275(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), VARIANTS ARG-195; VAL-783
RP   AND PRO-1467, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15067362;
RA   Date S., Nibu Y., Yanai K., Hirata J., Yagami K., Fukamizu A.;
RT   "Finb, a multiple zinc finger protein, represses transcription of the human
RT   angiotensinogen gene.";
RL   Int. J. Mol. Med. 13:637-642(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), ALTERNATIVE SPLICING, AND
RP   VARIANTS ARG-195 AND VAL-783.
RX   PubMed=21703425; DOI=10.1016/j.ajpath.2011.03.038;
RA   Nitz M.D., Harding M.A., Smith S.C., Thomas S., Theodorescu D.;
RT   "RREB1 transcription factor splice variants in urologic cancer.";
RL   Am. J. Pathol. 179:477-486(2011).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1-324 (ISOFORM 1), AND VARIANTS ARG-195 AND PRO-1467.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 849-1687 (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   FUNCTION.
RC   TISSUE=Thyroid carcinoma;
RX   PubMed=8816445; DOI=10.1128/mcb.16.10.5335;
RA   Thiagalingam A., de Bustros A., Borges M., Jasti R., Compton D.,
RA   Diamond L., Mabry M., Ball D.W., Baylin S.B., Nelkin B.D.;
RT   "RREB-1, a novel zinc finger protein, is involved in the differentiation
RT   response to Ras in human medullary thyroid carcinomas.";
RL   Mol. Cell. Biol. 16:5335-5345(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1161-1687 (ISOFORM 1), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1161-1633 (ISOFORM 2), VARIANT PRO-1467, AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=10390538; DOI=10.1093/nar/27.14.2947;
RA   Zhang L., Zhao J., Edenberg H.J.;
RT   "A human Raf-responsive zinc-finger protein that binds to divergent
RT   sequences.";
RL   Nucleic Acids Res. 27:2947-2956(1999).
RN   [8]
RP   INTERACTION WITH NEUROD1, AND FUNCTION.
RX   PubMed=12482979; DOI=10.1128/mcb.23.1.259-271.2003;
RA   Ray S.K., Nishitani J., Petry M.W., Fessing M.Y., Leiter A.B.;
RT   "Novel transcriptional potentiation of BETA2/NeuroD on the secretin gene
RT   promoter by the DNA-binding protein Finb/RREB-1.";
RL   Mol. Cell. Biol. 23:259-271(2003).
RN   [9]
RP   INTERACTION WITH AR, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17550981; DOI=10.1210/me.2006-0503;
RA   Mukhopadhyay N.K., Cinar B., Mukhopadhyay L., Lutchman M., Ferdinand A.S.,
RA   Kim J., Chung L.W.K., Adam R.M., Ray S.K., Leiter A.B., Richie J.P.,
RA   Liu B.C.-S., Freeman M.R.;
RT   "The zinc finger protein Ras-responsive element binding protein-1 is a
RT   coregulator of the androgen receptor: implications for the role of the Ras
RT   pathway in enhancing androgenic signaling in prostate cancer.";
RL   Mol. Endocrinol. 21:2056-2070(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-231; SER-1167;
RP   SER-1174; SER-1175; SER-1219; SER-1225; THR-1315 AND SER-1653, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1167; SER-1174 AND SER-1175,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-161; SER-231;
RP   SER-1122; SER-1167; SER-1174; SER-1175 AND SER-1653, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-42; SER-161 AND
RP   SER-1475, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-161; SER-175;
RP   SER-180; SER-231; SER-1122; SER-1140; SER-1167; SER-1174; SER-1175 AND
RP   SER-1320, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-161 AND SER-1219, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-551 AND LYS-615, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-615, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-615 AND LYS-885, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-203 AND LYS-615, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-203; LYS-435; LYS-502; LYS-551;
RP   LYS-566; LYS-593; LYS-613; LYS-615; LYS-624; LYS-857; LYS-885 AND LYS-913,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Transcription factor that binds specifically to the RAS-
CC       responsive elements (RRE) of gene promoters (PubMed:9305772,
CC       PubMed:15067362, PubMed:8816445, PubMed:10390538, PubMed:17550981).
CC       Represses the angiotensinogen gene (PubMed:15067362). Negatively
CC       regulates the transcriptional activity of AR (PubMed:17550981).
CC       Potentiates the transcriptional activity of NEUROD1 (PubMed:12482979).
CC       Promotes brown adipocyte differentiation (By similarity). May be
CC       involved in Ras/Raf-mediated cell differentiation by enhancing
CC       calcitonin expression (PubMed:8816445). {ECO:0000250|UniProtKB:Q3UH06,
CC       ECO:0000269|PubMed:10390538, ECO:0000269|PubMed:12482979,
CC       ECO:0000269|PubMed:15067362, ECO:0000269|PubMed:17550981,
CC       ECO:0000269|PubMed:8816445, ECO:0000269|PubMed:9305772}.
CC   -!- SUBUNIT: Interacts with NEUROD1 (PubMed:12482979). Interacts with AR
CC       (PubMed:17550981). {ECO:0000269|PubMed:12482979,
CC       ECO:0000269|PubMed:17550981}.
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000269|PubMed:15067362,
CC       ECO:0000269|PubMed:17550981, ECO:0000269|PubMed:9305772}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=beta;
CC         IsoId=Q92766-1; Sequence=Displayed;
CC       Name=2; Synonyms=alpha;
CC         IsoId=Q92766-2; Sequence=VSP_026706;
CC       Name=3; Synonyms=gamma;
CC         IsoId=Q92766-3; Sequence=VSP_026707;
CC       Name=4;
CC         IsoId=Q92766-4; Sequence=VSP_026704, VSP_026705;
CC       Name=5; Synonyms=delta;
CC         IsoId=Q92766-5; Sequence=VSP_053540;
CC       Name=6; Synonyms=epsilon;
CC         IsoId=Q92766-6; Sequence=VSP_053538, VSP_053539;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, placenta, lung, liver, skeletal
CC       muscle, kidney and pancreas. Not found in the brain.
CC       {ECO:0000269|PubMed:8816445}.
CC   -!- SIMILARITY: Belongs to the krueppel C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB19094.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAC25598.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAC26118.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAH42910.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH42910.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=BAA23165.1; Type=Miscellaneous discrepancy; Note=Numerous sequencing errors.; Evidence={ECO:0000305};
CC       Sequence=AAC26118.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D49835; BAA23165.1; ALT_SEQ; mRNA.
DR   EMBL; AB019254; BAD32776.1; -; mRNA.
DR   EMBL; AB019351; BAD32778.1; -; mRNA.
DR   EMBL; AB019352; BAD32779.1; -; mRNA.
DR   EMBL; HM369360; ADO14468.1; -; mRNA.
DR   EMBL; HM369361; ADO14469.1; -; mRNA.
DR   EMBL; AL139095; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355336; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL589644; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC042910; AAH42910.1; ALT_SEQ; mRNA.
DR   EMBL; BC131599; AAI31600.1; -; mRNA.
DR   EMBL; U26914; AAB19094.1; ALT_FRAME; mRNA.
DR   EMBL; AF072825; AAC25598.1; ALT_FRAME; mRNA.
DR   EMBL; AF072826; AAC26118.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS34335.1; -. [Q92766-2]
DR   CCDS; CCDS34336.1; -. [Q92766-1]
DR   CCDS; CCDS54963.1; -. [Q92766-3]
DR   RefSeq; NP_001003698.1; NM_001003698.3. [Q92766-1]
DR   RefSeq; NP_001003699.1; NM_001003699.3. [Q92766-2]
DR   RefSeq; NP_001003700.1; NM_001003700.1. [Q92766-3]
DR   RefSeq; NP_001161816.1; NM_001168344.1. [Q92766-1]
DR   RefSeq; XP_006715220.1; XM_006715157.3.
DR   RefSeq; XP_011513097.1; XM_011514795.2.
DR   AlphaFoldDB; Q92766; -.
DR   BioGRID; 112153; 80.
DR   CORUM; Q92766; -.
DR   IntAct; Q92766; 39.
DR   STRING; 9606.ENSP00000369270; -.
DR   GlyGen; Q92766; 6 sites, 1 O-linked glycan (6 sites).
DR   iPTMnet; Q92766; -.
DR   PhosphoSitePlus; Q92766; -.
DR   SwissPalm; Q92766; -.
DR   BioMuta; RREB1; -.
DR   DMDM; 152031673; -.
DR   EPD; Q92766; -.
DR   jPOST; Q92766; -.
DR   MassIVE; Q92766; -.
DR   MaxQB; Q92766; -.
DR   PeptideAtlas; Q92766; -.
DR   ProteomicsDB; 75450; -. [Q92766-1]
DR   ProteomicsDB; 75451; -. [Q92766-2]
DR   ProteomicsDB; 75452; -. [Q92766-3]
DR   ProteomicsDB; 75453; -. [Q92766-4]
DR   Antibodypedia; 9691; 226 antibodies from 31 providers.
DR   DNASU; 6239; -.
DR   Ensembl; ENST00000334984.10; ENSP00000335574.6; ENSG00000124782.21. [Q92766-3]
DR   Ensembl; ENST00000349384.10; ENSP00000305560.10; ENSG00000124782.21. [Q92766-1]
DR   Ensembl; ENST00000379933.7; ENSP00000369265.3; ENSG00000124782.21. [Q92766-1]
DR   Ensembl; ENST00000379938.7; ENSP00000369270.2; ENSG00000124782.21. [Q92766-2]
DR   GeneID; 6239; -.
DR   KEGG; hsa:6239; -.
DR   MANE-Select; ENST00000379938.7; ENSP00000369270.2; NM_001003699.4; NP_001003699.1. [Q92766-2]
DR   UCSC; uc003mxb.4; human. [Q92766-1]
DR   AGR; HGNC:10449; -.
DR   CTD; 6239; -.
DR   DisGeNET; 6239; -.
DR   GeneCards; RREB1; -.
DR   HGNC; HGNC:10449; RREB1.
DR   HPA; ENSG00000124782; Low tissue specificity.
DR   MalaCards; RREB1; -.
DR   MIM; 602209; gene.
DR   neXtProt; NX_Q92766; -.
DR   OpenTargets; ENSG00000124782; -.
DR   Orphanet; 567; 22q11.2 deletion syndrome.
DR   PharmGKB; PA34864; -.
DR   VEuPathDB; HostDB:ENSG00000124782; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   GeneTree; ENSGT00940000157533; -.
DR   HOGENOM; CLU_002702_0_0_1; -.
DR   InParanoid; Q92766; -.
DR   OMA; DAFCTPD; -.
DR   OrthoDB; 5398957at2759; -.
DR   PhylomeDB; Q92766; -.
DR   TreeFam; TF332503; -.
DR   PathwayCommons; Q92766; -.
DR   SignaLink; Q92766; -.
DR   SIGNOR; Q92766; -.
DR   BioGRID-ORCS; 6239; 84 hits in 1192 CRISPR screens.
DR   ChiTaRS; RREB1; human.
DR   GeneWiki; RREB1; -.
DR   GenomeRNAi; 6239; -.
DR   Pharos; Q92766; Tbio.
DR   PRO; PR:Q92766; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q92766; protein.
DR   Bgee; ENSG00000124782; Expressed in buccal mucosa cell and 209 other tissues.
DR   ExpressionAtlas; Q92766; baseline and differential.
DR   Genevisible; Q92766; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0016604; C:nuclear body; TAS:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IMP:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:UniProtKB.
DR   GO; GO:0090336; P:positive regulation of brown fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; IMP:UniProtKB.
DR   GO; GO:0033601; P:positive regulation of mammary gland epithelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 8.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR46451; RAS-RESPONSIVE ELEMENT-BINDING PROTEIN 1; 1.
DR   PANTHER; PTHR46451:SF1; RAS-RESPONSIVE ELEMENT-BINDING PROTEIN 1; 1.
DR   Pfam; PF00096; zf-C2H2; 4.
DR   Pfam; PF13912; zf-C2H2_6; 2.
DR   Pfam; PF13909; zf-H2C2_5; 1.
DR   SMART; SM00355; ZnF_C2H2; 15.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 8.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 14.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 14.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Repressor; Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..1687
FT                   /note="Ras-responsive element-binding protein 1"
FT                   /id="PRO_0000047326"
FT   ZN_FING         66..88
FT                   /note="C2H2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         97..119
FT                   /note="C2H2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         125..147
FT                   /note="C2H2-type 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         208..230
FT                   /note="C2H2-type 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         235..258
FT                   /note="C2H2-type 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         316..338
FT                   /note="C2H2-type 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         643..665
FT                   /note="C2H2-type 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         671..693
FT                   /note="C2H2-type 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         699..722
FT                   /note="C2H2-type 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         753..775
FT                   /note="C2H2-type 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         790..815
FT                   /note="C2H2-type 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1246..1268
FT                   /note="C2H2-type 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1393..1415
FT                   /note="C2H2-type 13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1512..1534
FT                   /note="C2H2-type 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   ZN_FING         1540..1562
FT                   /note="C2H2-type 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00042"
FT   REGION          25..63
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          145..197
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          939..1008
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1084..1177
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1192..1233
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1268..1362
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1409..1513
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1524..1543
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1558..1687
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        25..40
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        172..197
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        940..964
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1090..1128
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1213..1233
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1319..1346
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1412..1429
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1465..1513
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1525..1541
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1571..1589
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1590..1614
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1621..1638
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         36
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         161
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         180
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         231
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         970
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UH06"
FT   MOD_RES         1122
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1134
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UH06"
FT   MOD_RES         1135
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UH06"
FT   MOD_RES         1140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1167
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1174
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1219
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1225
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1315
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1320
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1475
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1585
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UH06"
FT   MOD_RES         1598
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UH06"
FT   MOD_RES         1653
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   CROSSLNK        203
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        435
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        502
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        551
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        566
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        593
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        613
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        615
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        615
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        624
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        857
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        885
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        913
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..1200
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_026704"
FT   VAR_SEQ         300..314
FT                   /note="AWCETNLRRCISEQH -> GKGHTNVRPASEPSP (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:21703425"
FT                   /id="VSP_053538"
FT   VAR_SEQ         315..1687
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:21703425"
FT                   /id="VSP_053539"
FT   VAR_SEQ         1201..1268
FT                   /note="EDNTQDEVAGAPADHHGPSDEEQGSPPEDKLLRAKRNSYTNCLQKITCPHCP
FT                   RVFPWASSLQRHMLTH -> MLTHTGQKPFPCQKCDAFFSTKSNCERHQLRKHGVTTCS
FT                   LRRNGLIPQSKESDVGSHDS (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_026705"
FT   VAR_SEQ         1269
FT                   /note="T -> TGQKPFPCQKCDAFFSTKSNCERHQLRKHGVTTCSLRRNGLIPQSKE
FT                   SDVGSHDST (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10390538,
FT                   ECO:0000303|PubMed:15067362"
FT                   /id="VSP_026706"
FT   VAR_SEQ         1270..1535
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:21703425"
FT                   /id="VSP_053540"
FT   VAR_SEQ         1270..1534
FT                   /note="DSQSDAETAAAAGEVLDLTSRDREQPSEGATELRQVAGDAPVEQATAETASP
FT                   VHREEHGRGESHEPEEEHGTEESTGDADGAEEDASSNQSLDLDFATKLMDFKLAEGDGE
FT                   AGAGGAASQEQKLACDTCGKSFKFLGTLSRHRKAHGRQEPKDEKGDGASTAEEGPQPAP
FT                   EQEEKPPETPAEVVESAPGAGEAPAEKLAEETEGPSDGESAAEKRSSEKSDDDKKPKTD
FT                   SPKSVASKADKRKKVCSVCNKRFWSLQDLTRHMRSH -> GQKPFPCQKCDAFFSTKSN
FT                   CERHQLRKHGVTTCSLRRNGLIPQSKESDVGSHDS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15067362"
FT                   /id="VSP_026707"
FT   VARIANT         195
FT                   /note="G -> R (in dbSNP:rs1334576)"
FT                   /evidence="ECO:0000269|PubMed:15067362,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:21703425"
FT                   /id="VAR_033197"
FT   VARIANT         783
FT                   /note="G -> V (in dbSNP:rs9502564)"
FT                   /evidence="ECO:0000269|PubMed:15067362,
FT                   ECO:0000269|PubMed:21703425"
FT                   /id="VAR_033198"
FT   VARIANT         1171
FT                   /note="D -> N (in dbSNP:rs9379084)"
FT                   /id="VAR_033199"
FT   VARIANT         1384
FT                   /note="G -> R (in dbSNP:rs2281833)"
FT                   /id="VAR_033200"
FT   VARIANT         1467
FT                   /note="L -> P (in dbSNP:rs2256596)"
FT                   /evidence="ECO:0000269|PubMed:10390538,
FT                   ECO:0000269|PubMed:15067362, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_033201"
FT   VARIANT         1499
FT                   /note="S -> Y (in dbSNP:rs35742417)"
FT                   /id="VAR_033202"
FT   CONFLICT        574
FT                   /note="A -> T (in Ref. 3; ADO14469)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        866
FT                   /note="Q -> K (in Ref. 6; AAB19094)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        994
FT                   /note="A -> V (in Ref. 3; ADO14469)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1148
FT                   /note="G -> R (in Ref. 6; AAB19094)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1321
FT                   /note="P -> R (in Ref. 7; AAC25598/AAC26118)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1394..1395
FT                   /note="AC -> SS (in Ref. 7; AAC25598/AAC26118)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1429
FT                   /note="S -> T (in Ref. 6; AAB19094)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1436
FT                   /note="Q -> S (in Ref. 6; AAB19094)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1683
FT                   /note="L -> H (in Ref. 6; AAB19094)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1687 AA;  181420 MW;  33B5755B0243C64F CRC64;
     MTSSSPAGLE GSDLSSINTM MSAVMSVGKV TENGGSPQGI KSPSKPPGPN RIGRRNQETK
     EEKSSYNCPL CEKICTTQHQ LTMHIRQHNT DTGGADHSCS ICGKSLSSAS SLDRHMLVHS
     GERPYKCTVC GQSFTTNGNM HRHMKIHEKD PNSATATAPP SPLKRRRLSS KRKLSHDAES
     EREDPAPAKK MVEDGQSGDL EKKADEVFHC PVCFKEFVCK YGLETHMETH SDNPLRCDIC
     CVTFRTHRGL LRHNALVHKQ LPRDAMGRPF IQNNPSIPAG FHDLGFTDFS CRKFPRISQA
     WCETNLRRCI SEQHRFVCDT CDKAFPMLCS LALHKQTHVA ADQGQEKPQA TPLPGDALDQ
     KGFLALLGLQ HTKDVRPAPA EEPLPDDNQA IQLQTLKCQL PQDPGCTNLL SLSPFEAASL
     GGSLTVLPAT KDSIKHLSLQ PFQKGFIIQP DSSIVVKPIS GESAIELADI QQILKMAASA
     PPQISLPPFS KAPAAPLQAI FKHMPPLKPK PLVTPRTVVA TSTPPPLINA QQASPGCISP
     SLPPPPLKLL KGSVEAASNA HLLQSKSGTQ PHAATRLSLQ QPRAELPGQP EMKTQLEQDS
     IIEALLPLSM EAKIKQEITE GELKAFMTAP GGKKTPAMRK VLYPCRFCNQ VFAFSGVLRA
     HVRSHLGISP YQCNICDYIA ADKAALIRHL RTHSGERPYI CKICHYPFTV KANCERHLRK
     KHLKATRKDI EKNIEYVSSS AAELVDAFCA PDTVCRLCGE DLKHYRALRI HMRTHCGRGL
     GGGHKGRKPF ECKECSAAFA AKRNCIHHIL KQHLHVPEQD IESYVLAADG LGPAEAPAAE
     ASGRGEDSGC AALGDCKPLT AFLEPQNGFL HRGPTQPPPP HVSIKLEPAS SFAVDFNEPL
     DFSQKGLALV QVKQENISFL SPSSLVPYDC SMEPIDLSIP KNFRKGDKDL ATPSEAKKPE
     EEAGSSEQPS PCPAPGPSLP VTLGPSGILE SPMAPAPAAT PEPPAQPLQG PVQLAVPIYS
     SALVSSPPLV GSSALLSGTA LLRPLRPKPP LLLPKPPVTE ELPPLASIAQ IISSVSSAPT
     LLKTKVADPG PASTGSNTTA SDSLGGSVPK AATTATPAAT TSPKESSEPP APASSPEAAS
     PTEQGPAGTS KKRGRKRGMR SRPRANSGGV DLDSSGEFAS IEKMLATTDT NKFSPFLQTA
     EDNTQDEVAG APADHHGPSD EEQGSPPEDK LLRAKRNSYT NCLQKITCPH CPRVFPWASS
     LQRHMLTHTD SQSDAETAAA AGEVLDLTSR DREQPSEGAT ELRQVAGDAP VEQATAETAS
     PVHREEHGRG ESHEPEEEHG TEESTGDADG AEEDASSNQS LDLDFATKLM DFKLAEGDGE
     AGAGGAASQE QKLACDTCGK SFKFLGTLSR HRKAHGRQEP KDEKGDGAST AEEGPQPAPE
     QEEKPPETPA EVVESAPGAG EAPAEKLAEE TEGPSDGESA AEKRSSEKSD DDKKPKTDSP
     KSVASKADKR KKVCSVCNKR FWSLQDLTRH MRSHTGERPY KCQTCERTFT LKHSLVRHQR
     IHQKARHAKH HGKDSDKEER GEEDSENEST HSGNNAVSEN EAELAPNASN HMAVTRSRKE
     GLASATKDCS HREEKVTAGW PSEPGQGDLN PESPAALGQD LLEPRSKRPA HPILATADGA
     SQLVGME
//
